Immuron is currently running a multi-national, randomized controlled clinical study in the USA, Australia, and Israel. More than 20 sites across the world are participating including, Duke University, Cleveland Clinic, Universities of Virginia, Virginia Commonwealth, and prestigious Hospitals in these countries.
Many of the worlds leaders in NASH and Hepatology are involved in this study including Professor Arun Sanyal.
The Study is designed to evaluate the effect of IMM-124E on patients with NASH compared to placebo after 6 months of treatment. A total of 120 patients are expected to enroll in the study and the company is close to reaching 30% of this milestone.